Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC SOUTH SAN FRANCISCO, Calif ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results